{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:13:08Z","timestamp":1794244388485,"version":"4.9.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Surgeon"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.surge.2011.07.003","type":"journal-article","created":{"date-parts":[[2012,1,9]],"date-time":"2012-01-09T17:18:51Z","timestamp":1326129531000},"page":"43-52","source":"Crossref","is-referenced-by-count":21,"title":["Chemoprevention in colorectal cancer - where we stand and what we have learned from twenty year's experience"],"prefix":"10.1016","volume":"10","author":[{"given":"Shahe","family":"Boghossian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hawash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.surge.2011.07.003_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdq122","article-title":"Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer","author":"Chan","year":"2010","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.surge.2011.07.003_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/107327481001700102","article-title":"Current progress in targeted therapy for colorectal cancer","volume":"17","author":"Ortega","year":"2010","journal-title":"Cancer Control"},{"issue":"25","key":"10.1016\/j.surge.2011.07.003_bib3","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1200\/JCO.2009.21.8529","article-title":"Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411","volume":"27","author":"Crane","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.surge.2011.07.003_bib4","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1634\/theoncologist.2009-0071","article-title":"Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study","volume":"14","author":"Kozloff","year":"2009","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.surge.2011.07.003_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000229787","article-title":"Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer","volume":"77","author":"Sobrero","year":"2009","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.surge.2011.07.003_bib6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2174\/157488709789957682","article-title":"The use of bevacizumab and trastuzumab beyond tumor progression: a new avenue in cancer treatment?","volume":"4","author":"Meriggi","year":"2009","journal-title":"Rev Recent Clin Trials"},{"issue":"3\u20134","key":"10.1016\/j.surge.2011.07.003_bib7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000320609","article-title":"Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer","volume":"79","author":"Manzoni","year":"2010","journal-title":"Oncology"},{"issue":"34","key":"10.1016\/j.surge.2011.07.003_bib8","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1200\/JCO.2009.23.4344","article-title":"Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study","volume":"27","author":"Chibaudel","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.surge.2011.07.003_bib9","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","article-title":"KRAS mutation is predictive of response to cetuximab therapy in colorectal cancer","volume":"66","author":"Lievre","year":"2006","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.surge.2011.07.003_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1056\/NEJMc0904160","article-title":"BRAF mutation in metastatic colorectal cancer","volume":"361","author":"Tol","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.surge.2011.07.003_bib11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa0808268","article-title":"Chemotherapy, bevacizumab and cetuximab in metastatic colorectal cancer","volume":"360","author":"Tol","year":"2009","journal-title":"N Eng J Med"},{"issue":"6","key":"10.1016\/j.surge.2011.07.003_bib12","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00280-008-0811-x","article-title":"Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors","volume":"63","author":"Lin","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"issue":"33","key":"10.1016\/j.surge.2011.07.003_bib13","doi-asserted-by":"crossref","first-page":"22709","DOI":"10.1074\/jbc.M801319200","article-title":"Potential molecular mechanism for c-Src kinase-mediated regulation of intestinal cell migration","volume":"283","author":"Mathew","year":"2008","journal-title":"J Biol Chem"},{"issue":"4 Suppl. 2","key":"10.1016\/j.surge.2011.07.003_bib14","first-page":"S37","article-title":"Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic","volume":"1","author":"Kopetz","year":"2007","journal-title":"Gastrointest Cancer Res"},{"issue":"2","key":"10.1016\/j.surge.2011.07.003_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10585-008-9215-x","article-title":"Src activity alters alpha3 integrin expression in colon tumor cells","volume":"26","author":"Kline","year":"2009","journal-title":"Clin Exp Metastasis"},{"issue":"6","key":"10.1016\/j.surge.2011.07.003_bib16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2174\/138955706777435724","article-title":"SRC inhibitors as potential therapeutic agents for human cancers","volume":"6","author":"Trevino","year":"2006","journal-title":"Mini Rev Med Chem"},{"issue":"1","key":"10.1016\/j.surge.2011.07.003_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12263-008-0081-6","article-title":"Estrogens, phytoestrogens and colorectal neoproliferative lesions","volume":"3","author":"Barone","year":"2008","journal-title":"Genes Nutr"},{"issue":"5","key":"10.1016\/j.surge.2011.07.003_bib18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1046\/j.1524-4741.2003.09510.x","article-title":"Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature","volume":"9","author":"Pietras","year":"2003","journal-title":"Breast J"},{"issue":"4","key":"10.1016\/j.surge.2011.07.003_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.drup.2005.06.002","article-title":"New approaches to reverse resistance to hormonal therapy in human breast cancer","volume":"8","author":"Weinberg","year":"2005","journal-title":"Drug Resist Updat"},{"issue":"15","key":"10.1016\/j.surge.2011.07.003_bib20","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1158\/0008-5472.CAN-09-0506","article-title":"Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells","volume":"69","author":"Hartman","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.surge.2011.07.003_bib21","article-title":"Expression of estrogen beta receptors in colon cancer progression","author":"Francesca","year":"2007","journal-title":"Diagn Mol Pathol"},{"issue":"1","key":"10.1016\/j.surge.2011.07.003_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.canlet.2008.10.050","article-title":"The inhibitory effect of diarylpropionitrile, a selective agonist of estrogen receptor beta, on the growth of MC38 colon cancer line","volume":"276","author":"Motylewska","year":"2009","journal-title":"Cancer Lett"},{"issue":"23","key":"10.1016\/j.surge.2011.07.003_bib23","doi-asserted-by":"crossref","first-page":"9118","DOI":"10.1158\/0008-5472.CAN-09-2348","article-title":"Estradiol alters cell growth in nonmalignant colonocytes and reduces the formation of preneoplastic lesions in the colon","volume":"69","author":"Weige","year":"2009","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.surge.2011.07.003_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00001813-200201000-00001","article-title":"Histone deacetylase inhibitors in cancer treatment","volume":"13","author":"Vigushin","year":"2002","journal-title":"Anticancer Drugs"},{"issue":"19","key":"10.1016\/j.surge.2011.07.003_bib25","doi-asserted-by":"crossref","first-page":"10367","DOI":"10.1073\/pnas.94.19.10367","article-title":"Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens","volume":"94","author":"Fahey","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.surge.2011.07.003_bib26","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.3945\/jn.109.113332","article-title":"Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention","volume":"139","author":"Ho","year":"2009","journal-title":"J Nutr"},{"issue":"3","key":"10.1016\/j.surge.2011.07.003_bib27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.14712\/18059694.2017.78","article-title":"In\u00a0vitro antiproliferative effects of sulforaphane on human colon cancer cell line SW620","volume":"50","author":"Andelova","year":"2007","journal-title":"Acta Med (Hradec Kralove)"},{"issue":"9","key":"10.1016\/j.surge.2011.07.003_bib28","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.fct.2009.06.034","article-title":"Activation of several concurrent proapoptic pathways by sulforaphane in human colon cancer cells SW620","volume":"47","author":"Rudolf","year":"2009","journal-title":"Food Chem Toxicol"},{"issue":"20","key":"10.1016\/j.surge.2011.07.003_bib29","doi-asserted-by":"crossref","first-page":"9937","DOI":"10.1158\/0008-5472.CAN-07-1112","article-title":"Chemoprevention of familial adenomatous polyposis by natural dietary compounds sulforaphane and dibenzoylmethane alone and in combination in ApcMin\/+ mouse","volume":"67","author":"Shen","year":"2007","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.surge.2011.07.003_bib30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00280-001-0390-6","article-title":"Phenylbutyrate-induced apoptosis is associated with inactivation of NF-kappaB IN HT-29 colon cancer cells","volume":"49","author":"Feinman","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1\u20134","key":"10.1016\/j.surge.2011.07.003_bib31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/biof.5520120142","article-title":"Butyrate as a model for \"gene-regulating chemoprevention and chemotherapy.\"","volume":"12","author":"Sowa","year":"2000","journal-title":"Biofactors"},{"issue":"2","key":"10.1016\/j.surge.2011.07.003_bib32","first-page":"995","article-title":"Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer","volume":"27","author":"Sung","year":"2007","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.surge.2011.07.003_bib33","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/mc.20378","article-title":"1,1-bis(3\u2019-indolyl)-1-(p-methoxyphenyl)methane activates Nur77-independent proapoptotic responses in colon cancer cells","volume":"47","author":"Cho","year":"2008","journal-title":"Mol Carcinog"},{"issue":"6","key":"10.1016\/j.surge.2011.07.003_bib34","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/1940-6207.CAPR-08-0142","article-title":"3,3\u2019-diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin","volume":"2","author":"Bhatnagar","year":"2009","journal-title":"Cancer Prev Res (Phila Pa)"},{"issue":"17","key":"10.1016\/j.surge.2011.07.003_bib35","doi-asserted-by":"crossref","first-page":"5994","DOI":"10.1158\/0008-5472.CAN-04-0399","article-title":"1,1-Bis(3\u2019-indolyl)-1-(p-substitutedphenyl)methanes induce peroxisome proliferator-activated receptor gamma-mediated growth inhibition, transactivation, and differentiation markers in colon cancer cells","volume":"64","author":"Chintharlapalli","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.surge.2011.07.003_bib36","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/1471-2407-9-332","article-title":"A study protocol to investigate the relationship between dietary fibre intake and fermentation, colon cell turnover, global protein acetylation and early carcinogenesis: the FACT study","volume":"9","author":"Corfe","year":"2009","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.surge.2011.07.003_bib37","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/j.1349-7006.2008.00948.x","article-title":"Antitumor activities of synthetic and natural stilbenes through antiangiogenic action","volume":"99","author":"Kimura","year":"2008","journal-title":"Cancer Sci"},{"issue":"9","key":"10.1016\/j.surge.2011.07.003_bib38","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.bcp.2009.06.109","article-title":"2,3\u2019,4,4\u2019,5\u2019-Pentamethoxy-trans-stilbene, a resveratrol derivative, is a potent inducer of apoptosis in colon cancer cells via targeting microtubules","volume":"78","author":"Li","year":"2009","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.surge.2011.07.003_bib39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ijc.11344","article-title":"Resveratrol analog (Z)-3,5,4\u2019-trimethoxystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization","volume":"107","author":"Schneider","year":"2003","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.surge.2011.07.003_bib40","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1002\/ijc.24264","article-title":"Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5fluoro-uracil sensitivity in human derived colon cancer cells","volume":"124","author":"Colin","year":"2009","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.surge.2011.07.003_bib41","first-page":"217","article-title":"Significance of\u00a0wine and resveratrol in cardiovascular disease: French\u00a0paradox revisited","volume":"11","author":"Vidavalur","year":"2006","journal-title":"Exp Clin Cardiol"},{"issue":"10","key":"10.1016\/j.surge.2011.07.003_bib42","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/carcin\/bgn128","article-title":"(-)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells","volume":"29","author":"Adachi","year":"2008","journal-title":"Carcinogenesis"},{"issue":"4","key":"10.1016\/j.surge.2011.07.003_bib43","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/1940-6207.CAPR-08-0045","article-title":"(-)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL\/KsJ-db\/db mice","volume":"1","author":"Shimizu","year":"2008","journal-title":"Cancer Prev Res (Phila Pa)"},{"issue":"3","key":"10.1016\/j.surge.2011.07.003_bib44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10637-008-9158-8","article-title":"Hesperetin exerts dose dependent chemopreventive effect against 1,2-dimethyl hydrazine induced rat colon carcinogenesis","volume":"27","author":"Aranganathan","year":"2009","journal-title":"Invest New Drugs"},{"issue":"9","key":"10.1016\/j.surge.2011.07.003_bib45","first-page":"1546","article-title":"Chemopreventive effect of chitosan oligosaccharide against colon carcinogenesis","volume":"17","author":"Nam","year":"2007","journal-title":"J Microbiol Biotechnol"},{"issue":"6","key":"10.1016\/j.surge.2011.07.003_bib46","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/jcb.21152","article-title":"Chitosan prevents the development of AOM-induced aberrant crypt foci in mice and suppressed the proliferation of AGS cells by inhibiting DNA synthesis","volume":"100","author":"Lin","year":"2007","journal-title":"J Cell Biochem"},{"issue":"1","key":"10.1016\/j.surge.2011.07.003_bib47","first-page":"113","article-title":"Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D","volume":"11","author":"Holt","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3\u20135","key":"10.1016\/j.surge.2011.07.003_bib48","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jsbmb.2006.12.074","article-title":"Chemopreventive efficacy of 25-hydroxyvitamin D3 in colon cancer","volume":"103","author":"Murillo","year":"2007","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"8","key":"10.1016\/j.surge.2011.07.003_bib49","first-page":"3185","article-title":"Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt\/mTOR signaling","volume":"29","author":"Johnson","year":"2009","journal-title":"Anticancer Res"},{"issue":"9","key":"10.1016\/j.surge.2011.07.003_bib50","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/ijc.24593","article-title":"Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model","volume":"125","author":"Kunnumakkara","year":"2009","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.surge.2011.07.003_bib51","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00125-009-1440-6","article-title":"The influence of glucose-lowering therapies on cancer risk in type 2 diabetes","volume":"52","author":"Currie","year":"2009","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.surge.2011.07.003_bib52","first-page":"359","article-title":"[Biological role of AhR signaling pathway]","volume":"76","author":"Mimura","year":"2004","journal-title":"Seikagaku"},{"issue":"6","key":"10.1016\/j.surge.2011.07.003_bib53","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1158\/1078-0432.CCR-08-1870","article-title":"Novel dithiolethione-modified nonsteroidal anti-inflammatory drugs in human hepatoma HepG2 and colon LS180 cells","volume":"15","author":"Bass","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.surge.2011.07.003_bib54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejphar.2007.12.034","article-title":"Sulindac suppresses beta-catenin expression in human cancer cells","volume":"583","author":"Han","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.surge.2011.07.003_bib55","first-page":"435","article-title":"Inhibitory effects of 5-fluorouracil and oxaliplatin on human colorectal cancer cell survival are synergistically enhanced by sulindac sulfide","volume":"29","author":"Flis","year":"2009","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.surge.2011.07.003_bib56","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1053\/gast.2002.31890","article-title":"Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study","volume":"122","author":"Cruz-Correa","year":"2002","journal-title":"Gastroenterology"},{"issue":"14","key":"10.1016\/j.surge.2011.07.003_bib57","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJMoa012015","article-title":"Primary chemoprevention of familial adenomatous polyposis with sulindac","volume":"346","author":"Giardiello","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.surge.2011.07.003_bib58","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/1940-6207.CAPR-08-0042","article-title":"Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial","volume":"1","author":"Meyskens","year":"2008","journal-title":"Cancer Prev Res (Phila Pa)"},{"issue":"1","key":"10.1016\/j.surge.2011.07.003_bib59","first-page":"78","article-title":"Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis","volume":"6","author":"van Stolk","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.surge.2011.07.003_bib60","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jcb.20286","article-title":"Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells","volume":"94","author":"Zhu","year":"2005","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.surge.2011.07.003_bib61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/1471-2407-9-207","article-title":"Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer","volume":"9","author":"Doherty","year":"2009","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.surge.2011.07.003_bib62","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s10620-007-0139-0","article-title":"The COX-2 selective inhibitor-independent COX-2 effect on colon carcinoma cells is associated with the Delta1\/Notch1 pathway","volume":"53","author":"Zhang","year":"2008","journal-title":"Dig Dis Sci"},{"issue":"11","key":"10.1016\/j.surge.2011.07.003_bib63","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/jnci\/djj206","article-title":"Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors","volume":"98","author":"Grosch","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"10.1016\/j.surge.2011.07.003_bib64","doi-asserted-by":"crossref","first-page":"9409","DOI":"10.1073\/pnas.0902367106","article-title":"15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors","volume":"106","author":"Yan","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.surge.2011.07.003_bib65","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djn485","article-title":"Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials","volume":"101","author":"Cole","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.surge.2011.07.003_bib66","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1940-6207.CAPR-08-0206","article-title":"Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial","volume":"2","author":"Bertagnolli","year":"2009","journal-title":"Cancer Prev Res (Phila Pa)"},{"issue":"6","key":"10.1016\/j.surge.2011.07.003_bib67","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1053\/j.gastro.2006.08.079","article-title":"A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas","volume":"131","author":"Baron","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.surge.2011.07.003_bib68","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7326\/0003-4819-146-5-200703060-00010","volume":"146","author":"Rostom","year":"2007","journal-title":"Ann Intern Med"},{"issue":"14","key":"10.1016\/j.surge.2011.07.003_bib69","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1158\/0008-5472.CAN-05-4619","article-title":"Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice","volume":"66","author":"Swamy","year":"2006","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.surge.2011.07.003_bib70","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/gut.2009.203000","article-title":"Effect of aspirin and NSAIDs on risk and survival from colorectal cancer","volume":"59","author":"Din","year":"2010","journal-title":"Gut"}],"container-title":["The Surgeon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1479666X11001004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1479666X11001004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T11:43:13Z","timestamp":1713354193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1479666X11001004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S1479666X11001004"],"URL":"https:\/\/doi.org\/10.1016\/j.surge.2011.07.003","relation":{},"ISSN":["1479-666X"],"issn-type":[{"value":"1479-666X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}